Ascendis Pharma A/S Provides Pipeline Update and Reviews Progress Towards Vision 3x3 at 38th Annual J.P. Morgan Healthcare Conference
12 janv. 2020 19h45 HE
|
Ascendis Pharma
COPENHAGEN, Denmark, Jan. 12, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address significant...
Ascendis Pharma Expands TransCon™ PTH Phase 2 PaTH Forward Clinical Trial to Expedite Enrollment of Subjects Previously Treated with NATPARA® in the United States
14 nov. 2019 16h01 HE
|
Ascendis Pharma
- Reflects company values and commitment to patients living with hypoparathyroidism - - Top-line data from expanded PaTH Forward Trial expected in first quarter of 2020 - - Company expects to exceed...
Ascendis Pharma A/S Reports First Quarter 2019 Financial Results
30 mai 2019 16h02 HE
|
Ascendis Pharma A/S
– Continued execution of global endocrinology rare disease programs, following validation of TransCon™ platform in phase 3 heiGHt Trial – – R&D Day on June 26 to feature endocrinology and...
Ascendis Pharma Announces Results of Study at ENDO 2019 Evaluating Impact of Hypoparathyroidism on Patient Quality-of-Life
25 mars 2019 14h00 HE
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, March 25, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address unmet medical...
Ascendis Pharma A/S Introduces Vision 3x3: A Strategic Roadmap Through 2025 to Achieve Sustainable Growth Using Multiple Approaches
07 janv. 2019 09h00 HE
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address significant...
Ascendis Pharma A/S Announces Dosing of Subjects in Phase 1 Trial of TransCon PTH
26 sept. 2017 08h00 HE
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, Sept. 26, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...